August 20, 2020

Michael T. Abrams, M.P.H., Ph.D.  
Health Researcher  
Public Citizen’s Health Research Group

Florian L. Muller, Ph.D.  
Professor  
MD Anderson Cancer Center

Michael A. Carome, M.D.  
Director  
Public Citizen’s Health Research Group

Victoria C. Yan  
Graduate Student  
MD Anderson Cancer Center

Sidney M. Wolfe, M.D.  
Founder and Senior Adviser  
Public Citizen’s Health Research Group

Dear Drs. Abrams, Carome, Wolfe, Muller, and Ms. Yan:

Thank you very much for your August 4, 2020 letter. You have provided important information worth further consideration, and Dr. Francis Collins has asked me to provide a response to you.

The National Center for Advancing Translational Sciences (NCATS) has the translational science tools, technologies, expertise, and collaborative networks that can be quickly applied to address urgent public health issues and research needs. NCATS is supporting several research activities to accelerate the efficient testing of potential therapeutics to address the novel coronavirus 2019 (SARS-CoV-2) and the disease it causes (COVID-19).

Scientists in our Division of Preclinical Innovation have reviewed the literature and agree that this compound merits further exploration. We are planning to independently test the therapeutic hypothesis for GS-441524 in treating SARS-CoV-2 infection and have informed our colleagues at NIAID about our plans for preclinical studies.

We expect to conduct these studies quickly and make the results available to the research community for further consideration. As we’ve done with many of our other COVID-19 efforts, NCATS will share the preclinical data we generate for GS-441524 with the scientific community on our Open Data Portal (https://opendata.ncats.nih.gov/covid19/) soon after the studies are completed.

Sincerely,

Christopher P. Austin, M.D.  
Director, National Center for Advancing Translational Sciences, NIH

cc: Daniel O’Day, M.B.A. Chairman and CEO, Gilead Sciences  
Stephen M. Hahn, M.D., Commissioner, Food and Drug Administration  
Gary L. Disbrow, Ph.D., Acting Director, Biomedical Advanced Research and Development Authority  
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases  
Francis S. Collins, M.D., Ph.D., Director, National Institutes of Health